On February 11, 2022 Syncromune, Inc., a clinical stage biopharmaceutical company focused on the development of intratumoral immunotherapy reported that Charles J. Link, M.D., Executive Chairman & Chief Medical Officer of Syncromune will deliver a presentation at the 2022 BIO CEO & Investor Conference (Press release, Syncromune, FEB 11, 2022, View Source [SID1234608040]). Taking place February 14 – 17, 2022 at the New York Marriot Marquis, the conference will feature a hybrid of virtual and in-person participation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Link will be highlighting Syncromune’s recent corporate achievements, including the recent completion of the in-licensing of four target assets. He will also review the company’s proprietary Syncrovax platform, which is a next-generation personalized cancer therapy being developed to optimize intratumoral immunotherapy for the treatment of metastatic solid tumors.

Members of the company’s executive team will be on site for one-on-one meetings with investors and companies. A copy of the presentation will be available on Syncromune’s website following the conclusion of the BIO CEO & Investor Conference.